

**Supplementary Information**  
**MEF2C shapes the microtranscriptome during differentiation of skeletal muscles**

Agnieszka Piasecka<sup>1</sup>, Michał Sekrecki<sup>1</sup>, Michał Wojciech Szcześniak<sup>2</sup> and Krzysztof Sobczak<sup>1,\*</sup>

<sup>1</sup> Laboratory of Gene Therapy, Department of Gene Expression, Institute of Molecular Biology and Biotechnology, Faculty of Biology, Adam Mickiewicz University, Uniwersytetu Poznańskiego 6, 61-614 Poznań, Poland

<sup>2</sup> Institute of Human Biology and Evolution, Faculty of Biology, Adam Mickiewicz University, Uniwersytetu Poznańskiego 6, 61-614 Poznań, Poland




Figure S1. Expression of muscle-specific genes in the differentiation of HSKMs (related to Fig. 1). (a) Skeletal muscle cells were cultured in growth medium (day 0) as myoblasts and induced to differentiation via changing the medium, and cells were harvested at various time points (12 h, and days 1, 2, 3 and 5) and RNA isolated for the analysis of gene expression. The relative mRNA levels of MEF2s,

SRF, MYOD1, MYF5 and MYOG were calculated based on RT-qPCR assays. Differences in gene expression are shown as fold changes normalized to GAPDH (mean from at least three experiments  $\pm$  SD). (b) MEF2C knock-down efficiency after 3, 4 and 5 days of differentiation. MEF2C level was determined in cells treated with siCTRL, siMEF2C\_1 or siMEF2C. The measurements were normalized to GAPDH (mean from at least three experiments  $\pm$  SD) (\*\*\*)  $P < 0.0001$ ). (c) mRNA level of paralogs of MEF2C, namely MEF2A and MEF2D, were not changed upon siRNA mediated MEF2C knock-down. The results were normalized to GAPDH (mean from at least three experiments  $\pm$  SD). (d) Myogenin protein level upon MEF2C knock-down according to western blot. Signal of MyoG was normalized to Tubulin. (mean from at least three experiments  $\pm$  SD).




Figure S2. **Changes in the expression level of miRNAs in HSKM cells with MEF2C depletion** (related to **Fig. 2**). (a) Relative expression changes of pri-miRNAs quantified by RT-qPCR assays; all data for pri-miRNA were normalized to GAPDH. Red bars represent miRNAs predicted to be downregulated according to RNA-seq data analysis from siMEF2C\_1 treated cells (\* Padj < 0.05). (b) Expression changes of miRNAs coming from the same pre-miRNA or from the same genetic clusters. Inside each bar specific value showing miRNAs baseMean count were introduced. (c) Figure 2d with introduced baseMean count value for each miRNA.




Figure S3. **Scheme of poly(A) tailing-based RT-qPCR modified to distinguish uridylated miRNA isoforms** (related to **Fig. 3**). Total RNA was poly(A) tailed using *E. coli* poly(A) polymerase. Poly(A)-tailed miRNAs were converted into cDNA in a reverse transcription reaction primed by a standard oligo-dT-anchor adaptor. Then, cDNA was amplified and quantitated by real-time PCR using an miRNA-specific forward primer and a universal reverse primer. The miRNA-specific forward primer is complementary to the 3' end of the miRNA and additionally contains three U residues; therefore, the method allows for preferential amplification of uridylated isoforms of miRNAs.




Figure S4. **Comparison of the number and length of U- and A-tailed reads from control and siMEF2C-treated myocytes** (related to Fig. 3). Total changes in 3'-nontemplated U- and A-nucleotide additions upon MEF2C depletion are depicted (top graphs). The 3' U- and A-tailed forms were further distinguished by the type of miRNA depends on its location within pre-miRNA (miRNA-3p or miRNA-5p) (\*P < 0.05).




Figure S5. (related to Fig. 3) **a) Comparison of the number and length of 3'-nontemplated U- and A-tailed reads of miRNAs in control and siMEF2C\_1 treated myocytes.** The X-axis represents the length of U- or A-tails, and the y-axis represents the percentile of modified reads in small RNA-seq. **b) The 3' U- and A- forms were further distinguished by the type of miRNA depending on the location of the pre-**

miRNA (miRNA-3p or miRNA-5p). The results of TruSeq Small RNA libraries sequencing. c) Accumulation of short fragments of miRNAs in HSkM cells upon siMEF2C\_2 depletion in RNA-seq data. Alterations in the level of miRNA fragments are shown as fold changes; fold change is defined as the ratio between the counts of short fragments of miRNA in siMEF2C\_2 KD and the counts of short fragments of miRNA in siCTRL cells divided by the counts of short fragments of miRNA in siCTRL cells (no change is equal to 1).







Figure S6. **TUT4 is a target for MEF2C** (related to Fig. 4). (a) Quantitative results of RT-qPCR analysis for MEF2C gene expression after treatment with siMEF2C\_1 and siMEF2C\_2. Results were normalized to GAPDH (\*\*\*)  $P < 0.0001$ ). (b) Quantitative RT-qPCR analysis of TUT4 expression after treatment with siMEF2C\_1 and siMEF2C\_2. Significant decrease of steady state level of TUT4 mRNA was observed upon MEF2C knock-down. Results were normalized to GAPDH (\*\*\*)  $P < 0.0001$ ). (c) TUT4 and MEF2C mRNA expression during human skeletal muscle cell differentiation. The results of RT-qPCR are the averages from three independent experiments normalized to GAPDH. (d) Quantitative RT-qPCR results for pre-mRNA of TUT4 after treatment with siMEF2C\_1 and siMEF2C\_2. Amplification performed with different pair of primers compare to experiments shown in Fig. 4c (primer Forward located in exon and Reverse in intron of TUT4). Results are averages from 3 experiments (+/- SD) normalized to GAPDH (\*  $P < 0.05$ , \*\*  $P < 0.01$ ). (e) Normalized luciferase activity calculated for Cos-7 cells cotransfected with genetic constructs expressing two isoforms of MEF2C (MEF2Ca1 and MEF2Ca2) or GFP and the LUC gene with either a control minimal promoter (miPLuc) or minimal promoter of LUC with upstream fragment of TUT4 gene

(miPftUT4). Sequence of minimal promotor is depicted in Supplementary Table S4. The experiment was performed in 5 replicates, and the P values were assessed by an unpaired Student's t-test (\*\* P<0.01).



**Figure S7. Mef2c contributes to the 3'-uridylation of miRNAs via TUT4 activity also in mouse myoblasts C2C12** (related to Fig. 4). (a) Results of RT-qPCR for mRNAs encoding for two main uridylyltransferases (Tut4 and Tut7), Mef2c and its target Myom1; (b) Reduction in the level of TUT4 protein in MEF2C KD conditions confirmed by western blotting. Quantification of TUT4 is depicted in the graph and based on 3 independent experiments normalized to Tubulin (\* $P < 0.05$ ); Signals were quantified with GeneTools from Syngene (<https://www.syngene.com/software/genetools-automatic-image-analysis/>). Fully uncut gel images are shown in Supplementary information, uncut images section. (c) Modified polyA-RT-qPCR assays were used to quantify uridylated isoforms of miR-221-U, miR-148b-U and miR-92a-U in C2C12 cells with Mef2c deficiency (\* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.0001$ ). Myoblasts with Tut4 or Tut4 and Tut7 knock-down were used as positive controls. The efficiency of Tut4 and Tut7 silencing is depicted on the right panel.




Figure S8. **The overlap of differentially expressed miRNAs in differentiated HSkM cells and in differentiated HSkM cells treated with siMEF2C\_1 or siMEF2C\_2** (related to Fig. 5). (a) Venn diagram illustrates the number of all 190 miRNAs with significantly altered expression in HSkM cells after 4 days of differentiation (HSkM differentiation) and miRNAs significantly changed upon differentiation of MEF2C-deficient HSkMs. Overlapping areas show miRNAs for which expression was significantly altered at two or all data sets (  $P_{adj} < 0.05$ ) (<http://www.biovenn.nl/index.php> was used to generate the diagram). (b) MEF2C and TUT4 protein level changes during HSkM differentiation (based on western blot). Quantification of MEF2C and TUT4 is depicted in the panel below western blots. Signals were quantified with GeneTools from Syngene (<https://www.syngene.com/software/genetools-automatic-image-analysis/>). Fully uncut gel images are shown in Supplementary information, uncut images section.

Supplementary Table S1

**siRNAs sequences**

<b>siRNA</b>	<b>Sequence (5'&gt;3')</b>
siMEF2C_1_s	P-GACCUGUCAUCUCUGUCUGGGUUUA
siMEF2C_1_as	P-UAAACCCAGACAGAGAUGACAGGUC
siMEF2C_2 SMARTpool	P-GACAAGGAAUGGGAGGAUA P-UAACACAGGUGGUCUGAUG P-GAAUAACCGUAAACCAGAU P-GAUCAGCAGGCAAAGAUUG
siCTRL_s	P-UAAGGCUAUGAAGAGAUACdTdT
siCTRL_as	P-GUAUCUCUUCAUAGCCUUAdTdT

Supplementary Table S2

Name of a primer	Sequence (5'>3')
MYF5 F	GTGGAGATCCTCAGGAATGC
MYF5 R	AGGTTGCTCTGAGGAGGTGA
MYOD1 F	AGCACTACAGCGGCGACT
MYOD1 R	AGGCAGTCTAGGCTCGACAC
MYOG F	AAGAGAAGCACCCCTGCTCAA
MYOG R	AGGTTGTGGGCATCTGTAGG
MyHCIIb F	ATGGCCATGATGACTCACCT
MyHCIIb R	CTTCCCTGCACCAGATTCTC
SRF F	GCCACTGGCTTTGAAGAGAC
SRF R	TCTTCAGCACAGTCCCATTG
MEF2A F	AGCTCCTCAGAGACCACCAA
MEF2A R	GGAGGGGAGACTTTGTAGG
MEF2D F	GTCATCACTTCCCAGGCAGGAA
MEF2D R	CGAATGAGTAGACTGGGAGA
MEF2C F	ATATGCAAGCAAATCTCCTCC
MEF2C R	GTTGCTACGGAAAACCACTGGGGTA
mMef2c F	GTCTGATGGGCGGAGATCTG
mMef2c R	CTTGCTGCCAGGTGGGATAA
MYOM1 F	TCGTGGTTGAAGAACGAGAA
MYOM1 R	CACCTTTCAGGGACTCCAAG
MYOZ F	CACAGCTGGTCAGGGATTCT
MYOZ R	CTGATCCTGTCTCACCAACC
MYOT F	CAAGAAAGATGCTGGGTGGT
MYOT R	CGCTGAAATTCTCCTTCTGG
TUT1 F	TCACCCAGAAAGCAGGAGAG
TUT1 R	GGTCAAAAGGGTCCTGGAGA
TUT2 F	CGGAGCAGTGATGGTGATTT
TUT2 R	CAGCACTAACGGACGAACTC
TUT4 F	ACACACTGGATTTTGGCTTTGGA
TUT4 R	TTTCCACCCTTCGTCTGAGG
mTut4 F	GGCGTGTCTCACAACCTGACT
mTut4 R	GCAAGGAAGAAGAGGGGGTT
mTut7 F	GAGGAGGCACCCAAAGAGAC
mTut7 R	CGATACGCTTTTTGGGCCAG
PARN F	AAGTGTACCAGGCCATAGAG
PARN R	CCATTTGTTAATGCAGAGACTG
PNPT1 F	GGATTCAGGGTTCCAATTT
PNPT1 R	TTTGCCACTGAAGCTTGTTG
Rrp41 F	GGGCCCTAGTGAAGTGTCAA
Rrp41 R	CTGCATAGGTCCCACCATCT
DIS3L2 F	GAGCCAGCACAGCAGGTC
DIS3L2 R	CAGGATGGCGCTGTACTTG
TUT4-3' UTR F	AGATAGCTAGCTCAGCTGGTCTACCGATGC
TUT4-3' UTR R	AGATATCTAGACAGACAAAATCAACTTTCATTCA
pre-mRNA TUT4 F	GTTACTCCCCATTCCCCACT

pre-mRNA TUT4 R	GGGAGGGGACATAATCCAGT
pre-mRNA TUT4 F2	GATTCCCGAGATGTTCTTGAC
pre-mRNA TUT4 R2	AGGTTTGC AACAGAGAGGAA
pri-miR-499a F	GGAGACAGACCCTCCCTCTT
pri-miR-499a R	GTCTTCACTTCCCTGCCAAA
pri-miR-128 F	CGGTGGA ACTCTGACTCCAT
pri-miR-128 R	GTTCGTGCTGCTCTTTGGAT
miR-92a-3p-U	GCACTTGTCCCGGCCTGTTTTT
miR-221-3p-U	CATTGTCTGCTGGGTTTCTTT
miR-362-5p	AATCCTTGGAACCTAGGTGT
miR-499a-5p	TTAAGACTTGCAGTGATGTT
miR-16	AGCAGCACGTAAATATTGGC
U6	GGATGACACGCAAATTCGTG
miR-22-3p	AAGCTGCCAGTTGAAGAACT
miR-1	TGGAATGTAAAGAAGTATGT
miR-21	AGCUUAUCAGACUGAUGUUG
miR-206	TGGAATGTAAGGAAGTGTGT
miR-133a	TGGTCCCCTTCAACCAGCTG
miR-133b	TGGTCCCCTTCAACCAGCTA
miR-92a	TATTGCACTTGTCCCGGCCT
miR-221-3p	CTACATTGTCTGCTGGGTTC
miR-500a	ATGCACCTGGGCAAGGATTC
miR-376a-3p	ATCATAGAGGAAAATCCACG
miR-376c-3p	AACATAGAGGAAAATCCACG
miR-483-3p	TCACTCCTCTCCTCCCGTCT
miR-7-5p	GGAAGACTAGTGATTTTGT
miR-378a	ACTGGACTTGGAGTCAGAAG
miR-148a	TCAGTGCACTACAGAACTTT
miR-532	CATGCCTTGAGTGTAGGACC
miR-361	TTATCAGAATCTCCAGGGGT
miR-27a-5p	AGGGCTTAGCTGCTTGTGAGC
TUT7 F	GGAAGCCACGGAAGACTAGA
TUT7 R	CTGCAGGTGTACTTTGTCTGT
pri-miR-22 F	GCAGAGGGCAACAGTTCTTC
pri-miR-22 R	CAGCGAGGTAAACAGCTTCC
pri-miR-483 F	GGAACCACTCCCTTCTTTCC
pri-miR-483 R	GTGAAATGGGCTCACAGGAT
pri-miR-378a F	TGTTGAAGATTGAACCGAGATGT
pri-miR-378a R	GTTCCCAGACCATGCCAGT
pri-miR-128 F	ATCCTGATGGCCCTTAGTCA
pri-miR-128 R	TGCCAAGCTGTTACAAACCA
pri-miR-500a F	TTGGGTGATGAGACTTGCAC
pri-miR-500a R	GATGTATTTGGGGCCTAGCA
pri-miR-130a F	AGGGTTCTGTAGTCTTGGGC
pri-miR-130a R	AGGACAGGACCCACTAAAGC
pri-miR-1-1 F	GGCAGTAGACTCCAGGGAAG
pri-miR-1-1 R	GACACAGGCAAAGTGACAGAAC
pri-miR-1-1 F2	AGAGCTTGAGGGAAACTCCAC
pri-miR-1-1 R2	ATCATCAGCAACGCTGACTC
pri-miR-133a-2 F	AGAGCTTGAGGGAAACTCCAC

pri-miR-133a-2 R	GACAGTCGATTTGGTTCCATTT
pri-miR-1-2 F	GCAAAAAGAATCAAACCAGGAC
pri-miR-1-2 R	CATTCCATAGCATTGTATGTTCA
pri-miR-1-2 F2	CTCATCCTGGTTTTTCTCCTTG
pri-miR-1-2 R2	AAGCATGCAGAAAGTCATAAGC
pri-miR-133a-1 F	GCAGGAAAACAGTAGGAAAGTG
pri-miR-133a-1 R	ACAAATGAAAACGTTGGTTGTC
pri-miR-206 F	TCCCAGTGATCTTCTCGCTAAG
pri-miR-206 R	GGAGATAGGGGTGTTTCAGGAAG
pri-miR-133b F	ACACACCAAGATACCTGCACAC
pri-miR-133b R	TGACTCCAGGACTCCTCTTCTC
pri-miR-23a F	ATGGGATTTGCTTCCTGTCA
pri-miR-23a R	ACTTGGTGTGGACCCTGCT
pri-miR-27a F	AGGGCTTAGCTGCTTGTGAG
pri-miR-27a R	CAAACCAACTGTGTTTCAGCTC
pri-miR-7-2 F	TCCAGGGAATTCTGAGGTGA
pri-miR-7-2 R	GGCTGGCACCATTAGGTAGA
pri-miR-7-3 F	CAGGTGAGAAGGAGGAGCTG
pri-miR-7-3 R	TTGTTTGCTTCCCTCCTTTG
pri-miR-222 F	TGCCCAATAATCTCTCTCAGG
pri-miR-222 R	ACCCTCAATGGCTCAGTAGC
pri-miR-7-1 F	GCTGCATTTTACAGCACCAA
pri-miR-7-1 R	GCCATGGTGTCTCAACCTTT
pri-miR-362 F	ACACAAAAGGGCAGGTGTC
pri-miR-362 R	GTCCAGGGCAATGATGAAGT
pri-miR-376c F	AAAGTCGGTGGACCTCAGAA
pri-miR-376c R	AGAAGGTTTCATCCCGGAAA
minimal promotor	AGAGGGTATATAATGGAAGCTCGACTTCCAG



Supplementary Table S3

DNA templates for *in vitro* transcription

microRNA precursor	Sequence of a microRNA precursor (5'>3')
pre-let7aT7	GAAAGACAGTAGATTGTATAGTTATCTCCCAGTGGTGGGTGTGACCCTAAAACCTAT ACAACCTACTACCTCCTATAGTGAGTCGTATTA
pre-miR-27bT7	GCAGAACTTAGCCACTGTGAACAAAGCGGAAACCAATCACTGTTACCAATCAGCT AAGCTCCTATAGTGAGTCGTATTA
pre-miR-424T7	ATAGCAGCGCCTCACGTTTTGAACCATTTAGAACACTTCAAACATGAATTGCTGC CTATAGTGAGTCGTATTA

## Supplementary Table S7

The putative binding sites for MEF2C localized within 1 kb genomic regions spanning each of the top 16 differentially expressed miRNAs in MEF2C deficient myocytes. The table gather the list of best occurrences in each input promoter, with gene name, oligo score (from 0 to 1), position with respect to the transcription start site of the gene (“Position” column), putative binding sequence and strand.

MIR NAME	Gene Name	Score	Position	Sequence	Strand
miR-378a	hg38_refGene_NR_029870	0.920157	28	TACCTAGAAATAGCA	+
miR-376c	hg38_refGene_NR_029861	0.900028	27	TAACCATAAATAACA	-
miR-30d	hg38_refGene_NR_029599	0.897296	-334	AGTTTCAAAATAGTA	-
miR-500a	hg38_refGene_NR_030224	0.894999	-706	TACATAAAAATAGAG	+
miR-486-2	hg38_refGene_NR_106984	0.88298	-258	AGGATAAAATTAGAC	-
miR-532	hg38_refGene_NR_030241	0.881182	-188	GGAATAAAAATAAAG	+
miR-7-2	hg38_refGene_NR_029606	0.878932	-396	TTACTAAAAAAAAAAA	+
miR-30a	hg38_refGene_NR_029504	0.872389	-892	CATCTAAAAACAAAT	+
miR-128-2	hg38_refGene_NR_029824	0.842474	-281	GATCAAAAATAATT	-
miR-486-1	hg38_refGene_NR_030161	0.826622	-534	AAGCCAGAAAGAAAA	+
miR-483	hg38_refGene_NR_030158	0.825365	-721	TTTATATAATTAATA	+
miR-376a-1	hg38_refGene_NR_029868	0.810732	-775	AACACAAAAGTAACA	-
miR-499a	hg38_refGene_NR_030223	0.801897	-890	CTTCTAACAATGGCA	-
miR-22	hg38_refGene_NR_029494	0.799839	-215	TGGCTGTAAACAGAC	-
miR-139	hg38_refGene_NR_029603	0.78962	-640	AGGACAAGGATAGCT	+
miR-133a-2	hg38_refGene_NR_029676	0.766324	-674	TACCCAGAGATACCA	+

Supplementary Table S8



Variants of mutated miPTUT4 plasmids, which have deleted putative MEF2C binding sites. Three distinct putative binding sites, within upstream region of TUT4, are marked with colors. Mutant miPmut1TUT4 has deleted site 1, marked in the first row of table with red; miPmut2TUT4 mutant has deleted site 1 and 2, marked in the first row of table with red and blue; miPmut3TUT4 mutant has deleted site 1, 2 and 3 marked in the first row of table with red, blue and green, respectively.



Construct name	TUT4 upstream sequence introduced into the plasmids
miPTUT4	<p>CAGCCAGATTGGGGTAAAATGCACTAACTCTGAACCCTAGTTTTTTTCATCCGTAAATGAGAGCAACAGTAC                      GTAACCTCACAGGGCTATCGTGAAGTGGAGCGTCCCTCTGTGACCTCTAACCCAGTCCCAGCCTGAGTCACAT                      TATAAGAAAA<u>TTTATAAGGCCTATCTTGTAATA</u>CTTAAGATTTAACATCTTCCCTTACCTCTACGTCC                      ACTCTTTTCATACCTTTTTCCCTGCCTAGCATGTGTCAAACCTCAAAGGACTGGGCACAGAGCACAGAGGTTG                      TGTGCTTTGTCCAGCTTTGAGGTCAGAGATTGG<u>CTAAATAAT</u>CTCTGAGGCTGGG<u>GTCTTAAAAAACA</u>  <u>ACAAAAACA</u>AACTAACA AAACCTTAAGTCCGTTCCGCCCGTGACTTTAAATAATTATGTAGAGGAATGT                      AATACGTTAAAAGCAAGGGGATGAGGGGGCCATTGATGGTAGATGGTTTTATGCCCGCCTGCAGCTAAAG                      AAATGATTTCTAAAACCTCTTTTGGGGGTGGGAGATGGAGTGCTCCAGAGATTTCTCTTCGAGCTCCTTCA                      TTCTGAACTGCCTGCCTTTTTCAAAGGAAAAAAGGTCCAGCTGCGGTGGGCTGGAGGCCGTGGTGAGTGGG                      TGGGGTTCGACCTGGCGGCTTCTCTGCCCGCTCCCTACCGTTGCTCCGAAGCCCGCTTGGGCTTCCGA                      GGGTCCGCCGAGGCTCGGGCCACGCCAGTCCGAGTGCCAGGCCAGAGGGTACCCATTCCAGGCCGGCCTT                      CCTCCCCAGGGGAGCAGCCTTGGGAGCGAGGCGCCGAGGCCGCCCTCGGCTCGGCTTCCAGCTCGGGGG                      CCTCGGCAGAGACTAGGAACCAGACTGGGGCAGCACTGGGGCGCCCGCCACCCCACTCCGGCAAGC                      GGGCGAATCAGCGCGCTAACCCGCGGCGCCAGCGGGCTGCGGGACCTCGCGACCTCCGCTCGGCGGCC                      CGCCCCGCGAGCCCGGGTGGCTCCCTCCCTCTGCCAGCGGCCCGCCCC</p>
miPmut1TUT4	<p>CAGCCAGATTGGGGTAAAATGCACTAACTCTGAACCCTAGTTTTTTTCATCCGTAAATGAGAGCAACAGTAC                      GTAACCTCACAGGGCTATCGTGAAGTGGAGCGTCCCTCTGTGACCTCTAACCCAGTCCCAGCCTGAGTCACAT                      TATAAGAAAA<u>TTTATAAGGCCTATCTTGTAATA</u>CTTAAGATTTAACATCTTCCCTTACCTCTACGTCC                      ACTCTTTTCATACCTTTTTCCCTGCCTAGCATGTGTCAAACCTCAAAGGACTGGGCACAGAGCACAGAGGTTG                      TGTGCTTTGTCCAGCTTTGAGGTCAGAGATTGG<u>CTAAATAAT</u>CTCTGAGGCTGGAAACCTTAAGTCCGTT                      CGCCGAAACCTTAAGTCCGTTCCGCCCGGTAGAGGAATGTAATACGTTAAAAGCAAGGGGATGAGGGGGC                      CCATTGATGGTAGATGGTTTTATGCCCGCTGCAGCTAAAGAAATGATCTCTAAAACCTCTTTTGGGGGTG                      GGAGATGGAGTGCTCCAGAGATTTCTCTTCGAGCTCCTTCACTTCTGAACTGCCTTTTTCAAAGGAAA                      AAAGGTCCAGCTGCGGTGGGCTGGAGGCCGTGGTGGTGGGGTTCGACCTGGCGGCTTCTCTGCC                      CGCTCCCTACCGTTGCTCCGAAGCCCGCTTGGGCTTCCGAGGGTCCGCCGAGGCTCGGGCCACGCCAGT                      CCGAGTGCCAGGCCAGAGGGTACCCATTCCAGGCCGGCCTTCTCCCCAGGGGGAGCAGCCTTGGGAGCGA                      GGCGCCGAGGCGGCCCTCGGGCTCGGCTTCCAGCTCGGGGGCTCGGCAGAGACTAGGAACCAGACTGGGG                      CAGCACTGGGGCGCCGCCACCCCACTCCGGCAAGCGGGCAATCAGCGCGGCTAACCCGCGGCGC                      CCAGGCGGGCTCGGGACCTCGCAGCTCCGCTCGCGGGCCCCGCCCTGCCCGAGCCCGGGTGGCTC                      CCTCTCCCCCTGCCAGCGGCCCGCCCC</p>
miPmut2TUT4	<p>CAGCCAGATTGGGGTAAAATGCACTAACTCTGAACCCTAGTTTTTTTCATCCGTAAATGAGAGCAACAGTAC                      GTAACCTCACAGGGCTATCGTGAAGTGGAGCGTCCCTCTGTGACCTCTAACCCAGTCCCAGCCTGAGTCACTC                      GGGCGGAACGGACCTCAAGATTTAACATCTTCCCTTACCTCTACGTCCACTCTTTTCATACCTTTTTCCCT                      GCCTAGCATGTGTCAAACCTCAAAGGACTGGGCACAGAGCACAGAGGKTGKTGCTTTGTCCAGCTTTGAGG                      TCAGAGATTGG<u>CTAAATAAT</u>CTCTGAGGCTGGAACCTTAAGTCCGTTCCGCCGAAACCTTAAGTCCGTT                      CCGCCCGGTAGAGGAATGTAATACGTTAAAAGCAAGGGGATGAGGGGGCCATTGATGGTAGATGGTTTTA                      TGCCCGCCTGCAGCTAAAGAAATGATCTCTAAAACCTCTTTTGGGGGTGGGAGATGGAGTGCTCCAGAGAT                      TTCTCTTCGAGCTCCTTCACTTCTGAACTGCCTTTTTCAAAGGAAAAAAGGTCCAGCTGCGGTGGGCT                      GGAGGCCGTGGTGGTGGGTTGGGGTTCGACCTGGCGGCTTCTCTGCCCGCTCCCTACCGTTGCTCCGA                      AGCCCGCTTGGGCTTCCGAGGGTCCGCCGAGGCTCGGGCCACGCCAGTCCGAGTGCCAGGCCAGAGGGTA                      CCCATTCCAGGCCGGCCTTCTCCCCAGGGGGAGCAGCCTTGGGAGCGAGGCCCGAGGCGGCCCTCGGGC                      TCGGCTTCCAGCTCGGGGGCTCGGCAGAGACTAGGAACCAGACTGGGGCAGCACTGGGGCGCCCGCCACC                      CCCACCACTCCGGCAAGCGGGCAATCAGCGCGGCTAACCCGCGGCGCCAGGCGGGCTGCGGGACCTCG                      CGACCTCCGCTCGGCGGCCCGCCCTGCCCGAGCCCGGGTGGCTCCCTCTCCCCCTGCCAGCGGC                      CCGCCCC</p>
miPmut3TUT4	<p>CAGCCAGATTGGGGTAAAATGCACTAACTCTGAACCCTAGTTTTTTTCATCCGTAAATGAGAGCAACAGTAC                      GTAACCTCACAGGGCTATCGTGAAGTGGAGCGTCCCTCTGTGACCTCTAACCCAGTCCCAGCCTGAGTCACTC</p>




	GGGCGAACGGACCTCAAGATTTAACATCTTCCTTCACCTCTACGTCCACTCTTTTCATACCTTTTTCCT GCCTAGCATGTGTCAAACCTCAAAGGACTGGGCACAGAGCACAGAGGKTGKGTGCTTTGTCCAGCTTTGAGG TCAGAGATTGGTCTGAGGCTGGAAACCTTAAGTCCGTTCCGCCCAGAACCTTAAGTCCGTTCCGCCCAGTA GAGGAATGTAATACGTAAAAGCAAGGGGATGAGGGGGCCCATGATGGTAGATGGTTTTATGCCCGCCTG CAGCTAAAGAAATGATCTCTAAAACCTCTTTGGGGGTGGGAGATGGAGTGCTCCAGAGATTCTCTCGA GCTCCTTCATTCCTGAACTGCCTGCCTTTTCAAAGGAAAAAAGGTCCAGCTGCGGTGGGCTGGAGGCCGTG GTGAGTGGGTGGGGTTCGACCCTGGCGGCTTCCTCTGCCCCGCTCCCTACCGTTGCTCCGAAGCCCGCTG GGCTTCCGAGGTCCGCCGAGGCTCGGGCCACGCCAGTCCGAGTGCCAGGCCAGAGGGTACCCATTCCAG GCCGGCCTTCCTCCCCAGGGGAGCAGCCTTGGGAGCGAGGCGCCGAGGCGGCCCTCGGGCTCGGCTTCCA GCTCGGGGGCCTCGGCAGAGACTAGGAACCAGACTGGGGCAGCACTGGGGCGCCCGCCACCCCACT CCGGCAAGCGGGCGAATCAGCGGGCTAACCCGCGGCGCCAGGCGGGCTGCGGGACCTCGGACCTCCGC TCGGCGGCCCGCCCTGCCCGAGCCCCGGGTGGCTCCCTCCTCCCTCTGCCAGCGGCCCGCCCC
--	--

**Full length un-edited gel image of figures: 1a, 1d, 3e, 4b, S7b, S8b**


Full gel images for PCR results show in Figure 1a. Fragments presented in Fig. 1a are indicated by red rectangles.








Full gel images for western blot results show in Figure 1d. Fragments presented in Fig. 1d are indicated by red rectangles.







Full gel image for uridylation assay results show in Figure 3e. Fragment presented in Fig. 3e is indicated by red rectangle.



Full gel images for western blot results show in Figure **4b**. Fragments presented in Fig. **4b** are indicated by red rectangles.



Full gel images for western blot results show in Figure **S7b**. Fragments presented in Fig. **S7b** are indicated by red rectangles. Additional full gel images were taken with visible molecular weight size marker (M).



Full gel images for western blot results show in Figure **S8b**. Fragments presented in Fig. **S8b** are indicated by red rectangles. Additional full gel images were taken with visible molecular weight size marker (M).

Fig.S8b, right panel




Fig.S8b, left panel

